Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O4UZ
|
|||
| Former ID |
DIB015469
|
|||
| Drug Name |
Gp41 HIV-1 vaccine
|
|||
| Synonyms |
FIV inhibitors, Mymetics; MYM-V101; N-36E; S-291; Anti-retrovirals, Mymetics; Gp41 HIV-1 vaccine (virosomes); Gp41-derived peptides, Mymetics; HIV-1 therapeutics, Mymetics; Gp41 HIV-1 vaccine (virosomes), Mymetics
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
Mymetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Glycoprotein 41 (HIV gp41) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01084343) Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.